Discover comprehensive details about Patisiran, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

The RNA interference (RNAi) therapeutic, patisiran (Onpattro; Alnylam), showed a statistically significant and clinically meaningful benefit on functional capacity, as measured by the 6-minute walk ...

Credit: Getty Images. The APOLLO-B study included patients 18 years of age and older with ATTR amyloidosis (hereditary or wild-type) with cardiomyopathy. Positive topline results were announced from a ...

FDA advisors conceded on Wednesday that the benefit-risk balance of patisiran (Onpattro) technically checks out in wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM, also known as ...

According to new research, patisiran maintains long-term kidney function in ATTR-PN. Long-term patisiran treatment maintained stable eGFR in patients with ATTR-PN and chronic kidney disease, ...

Patisiran continued to demonstrate benefit in hATTR with polyneuropathy at 5 years. Measures of disability, polyneuropathy, and quality of life showed modest changes. This is the longest study of an ...

• Patisiran injection should be given by intravenous (IV) injection directly into the vein only by the healthcare personnel. • Calculate the required dose of patisiran and withdraw the necessary ...

The US Food and Drug Administration on Monday declined to approve an expanded indication for patisiran (Onpattro, Alnylam Pharmaceuticals) for the treatment of transthyretin-amyloid cardiomyopathy ...

Alnylam has stepped up its commitment to pioneering RNAi drug patisiran by retooling its agreement with Sanofi. The revised deal returns full global control of the ATTR amyloidosis drug to Alnylam and ...

Hereditary transthyretin (TTR)-mediated amyloidosis (hATTR) is an inherited, progressively debilitating, and often fatal disease caused by mutations in the TTR gene. TTR protein is primarily produced ...

Alnylam Pharmaceuticals Inc ALNY released new results from an interim analysis of exploratory data from the open-label extension (OLE) period of the APOLLO-B Phase 3 study of patisiran, for the ...

(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) announced the FDA has issued a Complete Response Letter in response to the company's supplemental New Drug Application for patisiran for the treatment ...